Masters Capital Management LLC Acquires 650,000 Shares of Brainsway Ltd. Sponsored ADR $BWAY

Masters Capital Management LLC raised its holdings in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 65.0% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,650,000 shares of the company’s stock after acquiring an additional 650,000 shares during the period. Masters Capital Management LLC’s holdings in Brainsway were worth $21,928,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Brainsway during the first quarter worth approximately $40,000. Raymond James Financial Inc. acquired a new stake in shares of Brainsway in the second quarter worth $85,000. Bank of America Corp DE bought a new position in Brainsway during the third quarter worth $107,000. Royal Bank of Canada increased its position in Brainsway by 1,145.9% during the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after acquiring an additional 7,735 shares during the period. Finally, Centiva Capital LP acquired a new position in Brainsway during the 3rd quarter valued at $181,000. 30.11% of the stock is owned by institutional investors.

Brainsway Stock Performance

Shares of NASDAQ BWAY opened at $15.97 on Monday. The firm has a market capitalization of $640.88 million, a price-to-earnings ratio of 45.63 and a beta of 1.22. Brainsway Ltd. Sponsored ADR has a one year low of $5.68 and a one year high of $17.35. The business has a fifty day simple moving average of $15.02 and a 200 day simple moving average of $13.97.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $15.53 million for the quarter, compared to the consensus estimate of $14.63 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. On average, research analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BWAY. New Street Research reissued a “buy” rating on shares of Brainsway in a report on Friday. Wall Street Zen downgraded shares of Brainsway from a “buy” rating to a “hold” rating in a report on Saturday. BTIG Research initiated coverage on shares of Brainsway in a research report on Monday, July 20th. They set a “buy” rating and a $18.00 price objective for the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday, July 21st. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Brainsway in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.67.

Brainsway Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.